STUDIES IN PROCESS
Validating and progressing positive pre-clinical data into successful Phase I, II and III studies
PharmaJet has formed strategic alliances with leading pharmaceutical, biotechnology, academic institutions and healthcare companies to use our needle-free injection technology to enhance the delivery of injected medicines and vaccines, providing a safe alternative to traditional injection techniques. We have needle-free devices for Intradermal (ID), Subcutaneous (SC), and Intramuscular (IM) delivery in 0.5ml and 0.1mL dose volumes.
In collaboration with other leading biotechnology companies, we are leveraging our needle-free proprietary systems and technology expertise for the rapid development and delivery of vaccines and therapeutics to fight the COVID-19 pandemic.
Current partnerships include:
- Immunomic Therapeutics and EpiVax
- Abnova Corporation
- Genexine/International Pharmaceutical Development Consortium
- University of Cambridge/DIOSynvax
Additional collaborations will be announced over the coming months.
We are interested in collaboration opportunities with partners where our technology can enhance the delivery of injectables in areas such as biologics, vaccines, small molecules, and other therapeutic technology platforms. Our Needle-free Injection Systems effectively deliver:
- Low and high viscosity medicines
- Proteins and peptides
- Specialty drug therapies
- Nucleic acid-based vaccines and therapeutics
PharmaJet currently has active collaborations with a wide variety of partners including emerging biotechnology companies, established pharmaceutical companies, Armed Forces/DoD (Department of Defense), Federal Agencies, among others.